As a single agent and in combination with cytotoxic agents, cetuximab has been shown to improve overall survival, when compared to placebo or standard of care, in patients with metastatic KRAS and NRAS exon 2–4 wild-type (WT) colorectal cancer (CRC) [1–3]. Here, KRAS is linked to colorectal cancer.